Su1443 Self-Expandable Metal Stents As Definite Treatment for Esophageal Variceal Bleeding

2013 ◽  
Vol 77 (5) ◽  
pp. AB325 ◽  
Author(s):  
Ingrid L. Holster ◽  
Ernst J. Kuipers ◽  
Henk R. Van Buuren ◽  
Manon C. Spaander ◽  
Eric T. Tjwa
2013 ◽  
Vol 58 ◽  
pp. S255 ◽  
Author(s):  
I.L. Holster ◽  
E.J. Kuipers ◽  
H.R. van Buuren ◽  
M.C.W. Spaander ◽  
E.T.T.L. Tjwa

Endoscopy ◽  
2013 ◽  
Vol 45 (06) ◽  
pp. 485-488 ◽  
Author(s):  
I. Holster ◽  
E. Kuipers ◽  
H. van Buuren ◽  
M. Spaander ◽  
E. Tjwa

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
Àngels Escorsell ◽  
Jaime Bosch

Acute variceal bleeding (AVB) is a life-threatening complication in patients with cirrhosis. Hemostatic therapy of AVB includes early administration of vasoactive drugs that should be combined with endoscopic therapy, preferably banding ligation. However, failure to control bleeding or early rebleed within 5 days still occurs in 15–20% of patients with AVB. In these cases, a second endoscopic therapy may be attempted (mild bleeding in a hemodynamically stable patient) or we can use a balloon tamponade as a bridge to definitive derivative treatment (i.e., a transjugular intrahepatic portosystemic shunt). Esophageal balloon tamponade provides initial control in up to 80% of AVB, but it carries a high risk of major complications, especially in cases of long duration of tamponade (>24 h) and when tubes are inserted by inexperienced staff. Preliminary reports suggest that self-expandable covered esophageal metallic stents effectively control refractory AVB (i.e., ongoing bleeding despite pharmacological and endoscopic therapy or massive bleeding precluding endoscopic therapy) with a low incidence of complications. Thus, covered self-expanding metal stents may represent an alternative to the Sengstaken-Blakemore balloon for the temporary control of bleeding in treatment failures. Further studies are required to determine the role of this new device in AVB.


Endoscopy ◽  
2006 ◽  
Vol 38 (9) ◽  
pp. 896-901 ◽  
Author(s):  
R. Hubmann ◽  
G. Bodlaj ◽  
M. Czompo ◽  
L. Benkö ◽  
P. Pichler ◽  
...  

PLoS ONE ◽  
2015 ◽  
Vol 10 (6) ◽  
pp. e0126525 ◽  
Author(s):  
Martin Müller ◽  
Thomas Seufferlein ◽  
Lukas Perkhofer ◽  
Martin Wagner ◽  
Alexander Kleger

2016 ◽  
Vol 2016 ◽  
pp. 1-10 ◽  
Author(s):  
Xiao-Dong Shao ◽  
Xing-Shun Qi ◽  
Xiao-Zhong Guo

Background. Preliminary studies suggest that covered self-expandable metal stents may be helpful in controlling esophageal variceal bleeding.Aims. To evaluate the effectiveness and safety of esophageal stent in refractory variceal bleeding in a systematic review and meta-analysis.Methods. A comprehensive literature search was conducted on PubMed, EMBASE, and Cochrane Library covering the period from January 1970 to December 2015. Data were selected and abstracted from eligible studies and were pooled using a random-effects model. Heterogeneity was assessed usingI2test.Results. Five studies involving 80 patients were included in the analysis. The age of patients ranged from 18 to 91 years. The mean duration of follow-up was 46.8 d (range, 30–60 d). The success rate of stent deployment was 96.7% (95% CI: 91.6%–99.5%) and complete response to esophageal stenting was in 93.9% (95% CI: 82.2%–99.6%). The incidence of rebleeding was 13.2% (95% CI: 1.8%–32.8%) and the overall mortality was 34.5% (95% CI: 24.8%–44.8%). Most of patients (87.4%) died from hepatic or multiple organ failure, and only 12.6% of patients died from uncontrolled bleeding. There was no stent-related complication reported and the incidence of stent migration was 21.6% (95% CI: 4.7%–46.1%).Conclusion. Esophageal stent may be considered in patients with variceal bleeding refractory to conventional therapy.


2014 ◽  
Vol 13 (3) ◽  
pp. 364-369 ◽  
Author(s):  
Zuo-Hua Gan ◽  
Chen-Chi Tsai ◽  
Kuo-Chih Tseng ◽  
Chih-Chun Tsai ◽  
Yu-Hsi Hsieh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document